Clinical trial · Interventional
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
Efficacy, Safety and PK of CD7 CAR-T in Patients With Relapsed or Refractory CD7+ Hematological Malignancies
NCT05454241CI-TRIAL-00087178completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematological Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anti-CD7 CAR-T | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- anti-CD7 UCAR-T cells
- interventionNames
- Drug: Anti-CD7 CAR-T
Primary outcomes (1)
- measure
- Overall Response Rate(ORR)
- timeFrame
- 1 Year
- description
- Number of patients who achieved response after treatment of CD7 CAR-T cell.
Secondary outcomes (2)
- measure
- Duration of overall response (DOR)
- timeFrame
- 1 Year
- description
- Duration of overall response will be assessed from the CAR-T cell infusion to progression, death or last follow-up.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Diagnosed CD7 positive relapsed/refractory hematological malignancies. 2. Echocardiography shows left ventricular ejection fraction (LVEF) ≥ 50%; 3. There is no active pulmonary infection, and the oxygen saturation during air inhalation is more than 92%; 4. The estimated survival time is more than 3 months; 5. Eastern cooperative oncology group (ECOG) performance status of 0 to 2 6. The patients or their legal guardians voluntarily participated in the trial and signed the informed consent. Exclusion Criteria: 1. Patients with history of epilepsy or other central nervous system diseases; 2. Patients with prolonged QT or severe heart disease; 3. Pregnant or lactating women 4. Patients with uncontrolled active infection. 5. Positive for any of the following etiological tests: HIV, HBV, HCV 6. Any other conditions that researcher think it is inappropriate for the subject to anticipate the trial
References
Publications (0)
Data not yet available
No reference posted for this study.